PhD Student Researcher RUTGERS, The State University of New Jersey, USA Piscataway, New Jersey
The interest in messenger RNA (mRNA) based vaccines has grown unprecedentedly after their success with COVID-19 vaccines. Leveraging this advancement, mRNA encapsulated within lipid nanoparticle (LNP) delivery systems has emerged as a promising strategy. However, efficient delivery of mRNA has been a challenge due to problems of degradation and penetration into cells. Our study aimed to optimize formulation parameters to enhance cytocompatibility and encapsulation efficiency while minimizing the cytotoxic effects. Cell viability assessments on HEK293 cells revealed promising biocompatibility, with successful mRNA translation and binding observed. This indicates the potential of mRNA-LNP formulations in delivering payloads for various targets, such as cancer biomarkers. By harnessing immune response modulation similar to COVID-19 vaccines, these formulations hold promise for targeted tumor recognition and elimination. Further research refining design and delivery mechanisms is imperative to maximize therapeutic efficacy against cancer.
Learning Objectives:
Develop an approach to the translation of LNP-mRNA formulations in HEK293 cells
Evaluate the biocompatibility/cytotoxicity of LNP-mRNA formulations
Explain the advantages of using LNP-mRNA formulations as a drug delivery mechanism.
Deliver biomarkers for a targeted immunotherapy approach
